Aptatek BioSciences, a Princeton, NJ-based developer of in-home health monitoring solutions for patients with chronic disease, raised an undisclosed amount in funding based on the successful initial clinical evaluation of its first product.
The round was led by Canterbury Scientific, LDT, and the National PKU Alliance (NPKUA).
The company intends to use the funds to complete clinical studies of its groundbreaking in-home monitoring platform for phenylketonuria (PKU).
A spinout from Columbia University, Aptatek BioSciences is a point-of-care technology company with an aptamer-based assay chemistry developing products for in-home health monitoring.
Led by CEO Dr. Michael Boyce-Jacino, Aptatek is developing technologies for portable disease management devices that will improve patient compliance, wellness, and overall quality of life. Its proprietary aptamer design strategies and patented sequences create the opportunity for novel tests and new test strategies.
